Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ErbB-3/HER3 Protein, 200µg  

Recombinant human ErbB-3/HER3 Protein, 200µg

Recombinant Human ErbB-3 /HER3 Protein, With C-Fc Tag (rhErbB3-Fc) Ser20-Thr643 was produced in human 293 cells (HEK293)

Synonym: recombinant, human, protein ERBB3, ErbB-3, HER3, HER-3, Receptor tyrosine-protein kinase erbB-3

More details

ER3-H5259-200

Availability: within 7 days

408,00 €

Background
ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.[1-6]

Source
Recombinant Human ErbB-3 /HER3 Protein, With C-Fc Tag (rhErbB3-Fc) Ser20-Thr643 (Accession # NP_001973.2) was produced in human 293 cells (HEK293)

Molecular Characterization
rhErbB3-Fc, fused with Fc region of human IgG1 at C-terminus and has a calculated MW of 95.4 kDa after removal of signal peptide. The predicted N-terminal is Ser 20. Protein migrates as 130-140 kDa in reduced SDS-PAGE resulting from glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhErbB3-Fc by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Measured by its ability to inhibit the biological activity of Neuregulin1-β1 on MCF-7 human breast cancer cells. The ED50 for this effect is typically 1.5-6.0 μg/ml in the presence of 10 ng/ml Recombinant Human NRG1-β1/HRG1-β1 Extracellular Domain.

 

References

(1) Singer, E. etal., 2001, J. Biol. Chem. 276 (47): 44266–74
(2) Kraus,M.H.etal.,1989,Proc.Natl.Acad.Sci.86:9193-9197
(3) Carraway,K.L.etal.,1994,J.Biol.Chem.269:14303-14306
(4) Wallasch,C.etal.,1995,EMBO.J.14:4267-4275
(5) Alimandi,M.etal.,1995,Oncogene.10:1813-1821
(6) Gamett,D.C.etal.,1995,J.Biol.Chem.270:19022-19027